Evidence map›Paper›PMID 36920182›Full record

ArticleAging2023

Epimedin C protects dexamethasone-induced osteoblasts through NRF1/RhoA pathway.

Mi Huang, Lei Yu, Ying Wang, Chunlin Yang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Mi HuangWuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei 430022, China.
Lei YuWuhan Red Cross Hospital, Wuhan, Hubei 430000, China.
Ying WangCollege of Life Science Gannan Normal University, Jiangxi 341000, China.
Chunlin YangMedical Sciences Building MA202, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
South China Botanical Garden · CNUniversity of Missouri · USWuhan City Chinese Medicine Hospital · CNWuhan Red Cross Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis (OP) is a metabolic bone disease that leads to decrease of bone strength and increase bone brittle and fracture. Dexamethasone (DXMS) usage is a common risk factor of OP. In present study, we found that the Epimedin C protect the DXMS-induced OP, Ras Homolog Family Member A transforming protein (RhoA) was increased in osteoblasts (OBs) and OP models. We further revealed that Nrf1 is a transcription factor that responds to Epimedin C and DXMS in modulating RhoA promoter. The results collectively demonstrate that Epimedin C functions as a positive modifier of RhoA via alteration of Nrf1 transcriptional activity on RhoA promoter, thereby, protecting OBs against OP. Our work is the first study identifying the Epimedin C function in balancing the OBs in OP model via Nrf1-RhoA.

Indexed as

OsteoporosisrhoA GTP-Binding ProteinDexamethasoneFlavonoidsHumansNuclear Respiratory Factor 1OsteoblastsDexamethasoneepimedin CFlavonoidsNuclear Respiratory Factor 1rhoA GTP-Binding ProteinRHOA protein, humandexamethasoneepimedin CNRF1osteoporosisRhoA

Identifiers

PMID36920182
PMCPMC10085613
OpenAlexW4324138535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.